source
- Opinion: Mifepristone court ruling makes drug development riskier for everyoneThe 5th Circuit’s ruling on mifepristone “is bad for health care access, and it’s also bad for innovation,” writes Grace E. Colón.STAT · 3mo ago↗ source
- FDA search for new CBER head focused on small group of final candidatesThe FDA has narrowed its search for a new leader of its Center for Biologics Evaluation and Research to three or four final candidates, according to a person familiar with the matter. The agency ho…Endpoints · 3mo ago↗ source
- Celcuity strengthens case for ASCO-spotlighted breast cancer drugThe new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.BioPharma Dive